HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)
China · Delayed Price · Currency is CNY 2.930
-0.110 (-3.62%)
Nov 13, 2026, 3:04 PM CST
SHE:002437 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 1,897 | 2,135 | 2,441 | 2,626 | 3,108 | 3,145 |
Revenue Growth | -15.61% | -12.51% | -7.06% | -15.51% | -1.19% | 2.96% |
Gross Profit Gross Profit Growth | 859.79 | 966.36 | 1,303 | 1,530 | 1,746 | 2,312 |
Operating Income Operating Income Growth | 235.02 | 230.77 | 225.32 | 171.96 | 85.61 | 115.68 |
Net Income Net Income Growth | 381.29 | 376.91 | 232.76 | 120.33 | -291.33 | 45.04 |
Earnings Per Share EPS Growth | 0.17 | 0.17 | 0.10 | 0.05 | -0.13 | 0.02 |
EPS Growth | 34.77% | 63.85% | 88.12% | - | - | -88.74% |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Chemical Medicine Chemical Medicine Growth | 1,951 | 2,254 | 2,517 | 2,967 | 2,977 |
Traditional Chinese Medicine Traditional Chinese Medicine Growth | 180.56 | 182.09 | 100.96 | 134.54 | 148.43 |
Others Others Growth | 4.38 | 5.02 | 7.8 | 6.73 | 19.45 |
Total Total Growth | 2,135 | 2,441 | 2,626 | 3,108 | 3,145 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 1,120 | 930.06 | 511.96 | 711.28 | 1,288 | 1,496 |
Total Debt Total Debt Growth | 106.81 | 92.01 | 3.28 | 675.69 | 1,455 | 1,558 |
Net Cash (Debt) Net Cash Growth | 1,013 | 838.05 | 508.68 | 35.59 | -166.67 | -62.42 |
Net Cash Growth | 33.72% | 64.75% | 1329.47% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.46 | 0.37 | 0.22 | 0.02 | -0.08 | -0.03 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 248.27 | 273.36 | 410.94 | 274.18 | 261.62 | 274.18 |
Capital Expenditures CapEx Growth | -19.42 | -23.81 | -62.9 | -29.62 | -33.01 | -34.51 |
Free Cash Flow Free Cash Flow Growth | 228.85 | 249.54 | 348.04 | 244.55 | 228.6 | 239.67 |
Free Cash Flow Growth | -38.48% | -28.30% | 42.32% | 6.98% | -4.62% | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 45.32% | 45.25% | 53.40% | 58.27% | 56.17% | 73.52% |
Operating Margin | 12.39% | 10.81% | 9.23% | 6.55% | 2.76% | 3.68% |
Pretax Margin | 22.14% | 19.18% | 11.62% | 6.73% | -8.68% | 2.73% |
Profit Margin | 20.10% | 17.65% | 9.54% | 4.58% | -9.37% | 1.43% |
FCF Margin | 12.06% | 11.69% | 14.26% | 9.31% | 7.36% | 7.62% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 17.08 | 18.18 | 24.39 | 45.85 | - | 142.01 |
Forward PE | - | 27.91 | 26.21 | 24.55 | 24.55 | 24.55 |
P/FCF Ratio | 28.55 | 27.46 | 16.31 | 22.56 | 24.42 | 26.69 |
PS Ratio | 3.44 | 3.21 | 2.33 | 2.10 | 1.80 | 2.03 |